A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors

2024-9-14

Clinical characteristics, treatment, and outcomes of nivolumab induced immune thrombocytopenia

2024-9-12

Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer

2024-9-3

Retraction Note: The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells

2024-8-30

Treatment response to durvalumab plus tremelimumab after progression with previous immune checkpoint inhibitor in unresectable hepatocellular carcinoma

2024-8-30

Targeting multiple receptor tyrosine kinases with sitravatinib: A Phase 1b study in advanced renal cell carcinoma and castrate-resistant prostate cancer

2024-8-21

Depth of response and treatment outcomes of immune checkpoint inhibitor-based therapy in patients with advanced non-small cell lung cancer and high PD-L1 expression: An exploratory analysis of retrospective multicenter cohort

2024-8-21

Broad-spectrum anti-cancer activity of fused human arginase variants

2024-8-20

Design optimization of Fucoidan-coating Cationic Liposomes for enhance Gemcitabine delivery

2024-8-18

Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis

2024-8-14

Advancements of prodrug technologies for enhanced drug selectivity in pharmacotherapies

2024-8-13

Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system

2024-8-12

A randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants

2024-8-10

A phase I safety and efficacy clinical trial of plocabulin and gemcitabine in patients with advanced solid tumors

2024-8-3

Liposomal irinotecan (HR070803) in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors: a phase 1b dose-escalation and expansion study

2024-7-22

Clinical characteristics, diagnosis and management of nivolumab-induced myocarditis: hypersensitivity myocarditis, or something else

2024-7-17

Phase I study of trifluridine/tipiracil (TAS-102) plus irinotecan in combination with bevacizumab as a second-line therapy for patients with metastatic colorectal cancer

2024-7-11

Auger emitter in combination with Olaparib suppresses tumor growth via promoting antitumor immune responses in pancreatic cancer

2024-6-28

A novel recombinant adenovirus expressing apoptin and melittin genes kills hepatocellular carcinoma cells and inhibits the growth of ectopic tumor

2024-6-27

Study on the effects of rapamycin and the mTORC1/2 dual inhibitor OSI-027 on the metabolism of colon cancer cells based on UPLC-MS/MS metabolomics

2024-6-25

Radiosensitization effect of quinoline-indole-schiff base derivative 10E on non-small cell lung cancer cells in vitro and in tumor xenografts

2024-6-17

Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)

2024-6-6

177Lu−SN201 nanoparticle shows superior anti−tumor efficacy over conventional cancer drugs in 4T1 orthotopic model

2024-6-5

A first-in-human phase I trial of daily oral zelenirstat, a N-myristoyltransferase inhibitor, in patients with advanced solid tumors and relapsed/refractory B-cell lymphomas

2024-6-5

A phase 1/1b, open-label, dose-escalation study of PD-1 inhibitor, cetrelimab alone and in combination with FGFR inhibitor, erdafitinib in Japanese patients with advanced solid tumors

2024-6-4

Clinical characteristics, treatment and outcome of pembrolizumab-induced acute pancreatitis

2024-6-3

Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer

2024-5-29

Effect of PAWI-2 on pancreatic cancer stem cell tumors

2024-5-25

A phase 1 study to assess the absolute bioavailability, mass balance, pharmacokinetics, metabolism, and excretion of [14C]-mobocertinib, an oral inhibitor of EGFR exon 20 insertion mutations, in healthy participants

2024-5-24

Evolving or immutable - phase I solid tumor trials in the era of precision oncology

2024-5-22

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial

2024-5-20

In vitro results with minimal blood toxicity of a combretastatin A4 analogue

2024-5-17

The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer

2024-5-3

Toxicity burden patterns of MET-selective tyrosine kinase inhibitors: evidence from real-world pharmacovigilance

2024-5-3

Real-world evidence on treatment pattern, effectiveness, and safety of blinatumomab in Chinese patients with B-cell acute lymphoblastic leukemia

2024-4-25

The effect of food on the pharmacokinetics of Sutetinib maleate capsule, an irreversible EGFR tyrosine kinase inhibitor, in healthy Chinese subjects

2024-4-11

The suppression of cell motility through the reduction of FAK activity and expression of cell adhesion proteins by hAMSCs secretome in MDA-MB-231 breast cancer cells

2024-3-27

Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-mutated non-small cell lung cancer

2024-3-27

KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non–small-cell lung cancer

2024-3-26

Association between albumin–bilirubin grade and plasma trough concentrations of regorafenib and its metabolites M-2 and M-5 at steady-state in Japanese patients

2024-3-22

A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors

2024-3-14

Impact of carbamazepine on SMARCA4 (BRG1) expression in colorectal cancer: modulation by KRAS mutation status

2024-3-6

A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer

2024-3-5

The novel cytotoxic polybisphosphonate osteodex decreases bone resorption by enhancing cell death of mature osteoclasts without affecting osteoclastogenesis of RANKL-stimulated mouse bone marrow macrophages

2024-3-1

First-line treatment of driver gene-negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab?

2024-2-22

Targeting LEF1-mediated epithelial-mesenchymal transition reverses lenvatinib resistance in hepatocellular carcinoma

2024-2-19

A phase 1b open-label study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of py314 in combination with pembrolizumab in patients with advanced renal cell carcinoma

2024-2-19

Safety and efficacy of apatinib in combination with chemotherapy with or without immunotherapy versus chemotherapy alone as first-line treatment for advanced gastric cancer

2024-2-17

PD-1 inhibitor combined with albumin paclitaxel and apatinib as second-line treatment for patients with metastatic gastric cancer: a single-center, single-arm, phase II study

2024-2-12

Phase 1 study of pembrolizumab plus chemotherapy in Japanese patients with extensive-stage small-cell lung cancer

2024-2-1